Chapter 93: Cellicure (4)
If audio player doesn't work, press Stop then Play button again
Chapter 93: Cellicure (4)
Gu Sung-Woo, the Commissioner of the Korean Intellectual Property Office, was looking over the patent applications that came in this morning. These patents, which had been filed through the International Patent Cooperation Treaty (PCT), were documents that had come for the final approval stamp.
The Patent Cooperation Treaty was the standard model of international patents that pursued the protection of patents regarding inventions in more than one hundred fifty countries with an international patent treaty.
The patents that Lee Hae-Won spent several nights filing was now Goo Sung-Woos problem. A large pile of documents came into his office in a small cart.
What is this? he asked with wide eyes.
Its CEO Ryus from A-Bio.
Goo Sung-Woo covered his face with his hands after he heard the employee, who was moving the documents into his office. He figured out what this was after he heard that it was Young-Joons. This was well-known from the examination stage. They were all animal disease treatments, and there were one hundred twenty-two patents of them. The patent attorney had grouped it by disease when writing the statement instead of separating them into individual ones, but there were still thirty-two. Additionally, there were about four hundred pages for each patent statement written for every group.
Is the attorney who filed these still alive? asked Goo Sung-Woo as he stacked the documents on his desk.
I heard that the attorney went into Ryu Young-Joons company as the in-house patent attorney.
They wrote this, and theyre still working for him?
Yes.
Is it like Stockholm Syndrome or something?
I dont know. But the examiner used all his time off after this and disappeared.
...
Anyways, these are all the documents about the one hundred twenty-two new drugs. They have all been approved.
I didn't think they would actually all get approved. I think Ill get a cramp in my arm just from stamping it.
The patent examiners from other countries probably put their blood, sweat, and tears into this.
Phew. What can you do? It came in for priority review.
Starting with the first drug, Goo Sung-Woo began looking over them one by one.
* * *
The first group of livestock infectious diseases included rinderpest, hoof-and-mouth disease, swine fever, highly pathogenic avian influenza, vesicular stomatitis, Valley fever, Bluetongue, and sheep pox. The second group of diseases included tuberculosis, Aujeszkys disease, equine infectious anemia, nausea, rabies, chronic wasting disease, anaplasma, and Duck virus hepatitis. The third group of diseases included bovine ephemeral fever, akabane disease, avian mycoplasmosis, porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, avian encephalomyelitis, Mareks disease, and infectious bursal disease. It also included pet diseases for dogs and cats like the parvovirus infections and leptospirosis,
Patents for one hundred twenty-two drugs for a total of thirty-two groups of diseases were approved. There were basically three drugs for one disease, and there were two reasons for this. The first was to completely prevent competitive drugs from being discovered later and patented, and the second was to use another drug as a backup in case one drug does not work due to animal specificity.
These incredible drugs were examined from all over the world and approved.
[Ryu Young-Joon publishes patents for one hundred twenty-two types of animal diseases.]
[A-Bio CEO Ryu Young-Joon secures one hundred twenty-two animal drug patents personally.]
[How will all these drugs transform the livestock market and the pet industry?]
The news articles that were coming up one after another were more provocative than usual.
Professor Shin Jung-Ju appeared on the radio for the first time in a while.
CEO Ryu had commissioned these experiments to famous, mid-sized companies called Reaction Chemistry and Cell Bio. He spent over a million won on commission fees and patent publishing. And he succeeded in all of them.
Is this possible? How can an individual do something like this just with experiment agencies?
The interviewer asked.
Usually, they cant.
Some say that CEO Ryu may have registered personal patents by stealing internal data from A-Gen.
Haha, conspiracy theories like that are coming out because he succeeded in publishing an unbelievable amount of patents, but they will disappear soon. It is because A-Gen has never studied animal diseases before. No matter how talented the thief is, how could they steal something that doesnt exist?
Of course. But how did CEO Ryu do it?
No one knows. But there is something more surprising. Its that CEO RYu requested Reaction Chemistry to design a total of one hundred twenty-two drug candidates, and the number of animal experiments commissioned to Cell Bio was one hundred twenty-two. What do you think this means?
What does it mean?
Mckinney read the news report to Young-Joon.
It feels good to be complimented.
How is the diagnostic kit going? We can do this with certainty only if we have that.
We are working hard to develop it. Weve also found a way to lower the unit price as well, Young-Joon said.
I see. Mr. Ryu, when will you begin production?
I am on my way to meet the CEO of A-Gen to discuss that, he replied.
* * *
Young-Joon, who arrived at A-Gen, was alone with Yoon Dae-Sung.
I knew that you were smart and you made good drugs, but I didnt know that you filed one hundred twenty-two patents without A-Gen knowing, Yoon Dae-Sung said.
A-Gen had the idea, but didnt work on animal disease treatments.
Those patents. Theyre not A-Bios or A-Gens, but your own, right?
Yes.
Yoon Dae-Sung put his hand on his head like this was trouble.
Are you here to sell that to me?
You also know how much money these patents will generate. They wont just be produced at A-Gen, but pharma companies all over the world that are in the livestock industry will want to pay royalties and make the drug.
Of course, especially companies like Conson & Colson. They will do it since the United States is one of the countries with a powerful livestock industry.
Yes. But a patent is only a patent. Its another story from commercialization. You know that, right?
...
Yoon Dae-Sung understood what Young-Joon was trying to say. He was trying to make a deal with commercialization while he kept the patent.
I can make A-Gen the first to succeed at commercialization out of any company, Young-Joon said. The one hundred twenty-two drugs that were registered were all manufactured on the laboratory scale. They only make like five or ten milligrams. They were produced in a very rigorous process and were tested with a very pure formulation. But its not used like that in real industries. Everything changes when you manufacture a drug on a factory scale.
Yes.
Making a drug in a lab and manufacturing a drug in a factory was completely different. Lets say that it cost one million won to produce one dose of the drug in a lab. It couldnt be produced like that because the unit price was too expensive. The drug would be sold for over two million won including the distribution fee and profit margin in pharmacies, so who would buy something like that?
As such, the process of commercialization was an essential adjustment process that reduced the cost of production for factory manufacturing. In this process, everything changed, like the reaction buffer, the boiling equipment and column. Optimizing this was also a process of research and development.
As I am the developer of the one hundred twenty-two drugs, I also know how to make it into a factory scale.
And you are going to hand that over to A-Gen?
Yes, because I am a director of A-Gen. Its important to grow our company, right? We have to start producing before everyone else.
What do you want for it? Do you want the next CTO position when Nicholas term is over and it becomes vacant?
I will get that position even if you dont want me to, Young-Joon said.
...
The shareholders will support me a lot if I reveal that I have established all the commercialization methods and are going to supply them to A-Gen for free. It will be difficult for the CTO to hand over the position to someone else after his term ends in that atmosphere.
Then what do you want?
Yoon Dae-Sung gulped. He felt like Young-Joon was going to ask him to give up his seat. Right now, the shareholders were absolutely on Young-Joons side. Yoon Dae-Sung had no choice but to accept it, even if Young-Joon was asking for too much, since his management abilities would be seriously questioned if he declined sloppily and the commercialization methods went to Conson & Colson. And in Young-Joons perspective, it didnt matter who made the product as he would be the one making money.
Yoon Dae-Sung had been dragged along by Young-Joon several times, but he could never stop him, even if he knew. He couldnt even imagine what it is Young-Joon wanted
Is it shares?
Young-Joon smiled as he saw Yoon Dae-Sungs tense face.
Sir, you dont have to be so tense. I have no intention of asking for too much.
Please report us if you find any errors so we can fix it asap!
Chapter 93: Cellicure (4)
Gu Sung-Woo, the Commissioner of the Korean Intellectual Property Office, was looking over the patent applications that came in this morning. These patents, which had been filed through the International Patent Cooperation Treaty (PCT), were documents that had come for the final approval stamp.
The Patent Cooperation Treaty was the standard model of international patents that pursued the protection of patents regarding inventions in more than one hundred fifty countries with an international patent treaty.
The patents that Lee Hae-Won spent several nights filing was now Goo Sung-Woos problem. A large pile of documents came into his office in a small cart.
What is this? he asked with wide eyes.
Its CEO Ryus from A-Bio.
Goo Sung-Woo covered his face with his hands after he heard the employee, who was moving the documents into his office. He figured out what this was after he heard that it was Young-Joons. This was well-known from the examination stage. They were all animal disease treatments, and there were one hundred twenty-two patents of them. The patent attorney had grouped it by disease when writing the statement instead of separating them into individual ones, but there were still thirty-two. Additionally, there were about four hundred pages for each patent statement written for every group.
Is the attorney who filed these still alive? asked Goo Sung-Woo as he stacked the documents on his desk.
I heard that the attorney went into Ryu Young-Joons company as the in-house patent attorney.
They wrote this, and theyre still working for him?
Yes.
Is it like Stockholm Syndrome or something?
I dont know. But the examiner used all his time off after this and disappeared.
...
Anyways, these are all the documents about the one hundred twenty-two new drugs. They have all been approved.
I didn't think they would actually all get approved. I think Ill get a cramp in my arm just from stamping it.
The patent examiners from other countries probably put their blood, sweat, and tears into this.
Phew. What can you do? It came in for priority review.
Starting with the first drug, Goo Sung-Woo began looking over them one by one.
* * *
The first group of livestock infectious diseases included rinderpest, hoof-and-mouth disease, swine fever, highly pathogenic avian influenza, vesicular stomatitis, Valley fever, Bluetongue, and sheep pox. The second group of diseases included tuberculosis, Aujeszkys disease, equine infectious anemia, nausea, rabies, chronic wasting disease, anaplasma, and Duck virus hepatitis. The third group of diseases included bovine ephemeral fever, akabane disease, avian mycoplasmosis, porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, avian encephalomyelitis, Mareks disease, and infectious bursal disease. It also included pet diseases for dogs and cats like the parvovirus infections and leptospirosis,
Patents for one hundred twenty-two drugs for a total of thirty-two groups of diseases were approved. There were basically three drugs for one disease, and there were two reasons for this. The first was to completely prevent competitive drugs from being discovered later and patented, and the second was to use another drug as a backup in case one drug does not work due to animal specificity.
These incredible drugs were examined from all over the world and approved.
[Ryu Young-Joon publishes patents for one hundred twenty-two types of animal diseases.]
[A-Bio CEO Ryu Young-Joon secures one hundred twenty-two animal drug patents personally.]
[How will all these drugs transform the livestock market and the pet industry?]
The news articles that were coming up one after another were more provocative than usual.
Professor Shin Jung-Ju appeared on the radio for the first time in a while.
CEO Ryu had commissioned these experiments to famous, mid-sized companies called Reaction Chemistry and Cell Bio. He spent over a million won on commission fees and patent publishing. And he succeeded in all of them.
Is this possible? How can an individual do something like this just with experiment agencies?
The interviewer asked.
Usually, they cant.
Some say that CEO Ryu may have registered personal patents by stealing internal data from A-Gen.
Haha, conspiracy theories like that are coming out because he succeeded in publishing an unbelievable amount of patents, but they will disappear soon. It is because A-Gen has never studied animal diseases before. No matter how talented the thief is, how could they steal something that doesnt exist?
Of course. But how did CEO Ryu do it?
No one knows. But there is something more surprising. Its that CEO RYu requested Reaction Chemistry to design a total of one hundred twenty-two drug candidates, and the number of animal experiments commissioned to Cell Bio was one hundred twenty-two. What do you think this means?
What does it mean?
Mckinney read the news report to Young-Joon.
It feels good to be complimented.
How is the diagnostic kit going? We can do this with certainty only if we have that.
We are working hard to develop it. Weve also found a way to lower the unit price as well, Young-Joon said.
I see. Mr. Ryu, when will you begin production?
I am on my way to meet the CEO of A-Gen to discuss that, he replied.
* * *
Young-Joon, who arrived at A-Gen, was alone with Yoon Dae-Sung.
I knew that you were smart and you made good drugs, but I didnt know that you filed one hundred twenty-two patents without A-Gen knowing, Yoon Dae-Sung said.
A-Gen had the idea, but didnt work on animal disease treatments.
Those patents. Theyre not A-Bios or A-Gens, but your own, right?
Yes.
Yoon Dae-Sung put his hand on his head like this was trouble.
Are you here to sell that to me?
You also know how much money these patents will generate. They wont just be produced at A-Gen, but pharma companies all over the world that are in the livestock industry will want to pay royalties and make the drug.
Of course, especially companies like Conson & Colson. They will do it since the United States is one of the countries with a powerful livestock industry.
Yes. But a patent is only a patent. Its another story from commercialization. You know that, right?
...
Yoon Dae-Sung understood what Young-Joon was trying to say. He was trying to make a deal with commercialization while he kept the patent.
I can make A-Gen the first to succeed at commercialization out of any company, Young-Joon said. The one hundred twenty-two drugs that were registered were all manufactured on the laboratory scale. They only make like five or ten milligrams. They were produced in a very rigorous process and were tested with a very pure formulation. But its not used like that in real industries. Everything changes when you manufacture a drug on a factory scale.
Yes.
Making a drug in a lab and manufacturing a drug in a factory was completely different. Lets say that it cost one million won to produce one dose of the drug in a lab. It couldnt be produced like that because the unit price was too expensive. The drug would be sold for over two million won including the distribution fee and profit margin in pharmacies, so who would buy something like that?
As such, the process of commercialization was an essential adjustment process that reduced the cost of production for factory manufacturing. In this process, everything changed, like the reaction buffer, the boiling equipment and column. Optimizing this was also a process of research and development.
As I am the developer of the one hundred twenty-two drugs, I also know how to make it into a factory scale.
And you are going to hand that over to A-Gen?
Yes, because I am a director of A-Gen. Its important to grow our company, right? We have to start producing before everyone else.
What do you want for it? Do you want the next CTO position when Nicholas term is over and it becomes vacant?
I will get that position even if you dont want me to, Young-Joon said.
...
The shareholders will support me a lot if I reveal that I have established all the commercialization methods and are going to supply them to A-Gen for free. It will be difficult for the CTO to hand over the position to someone else after his term ends in that atmosphere.
Then what do you want?
Yoon Dae-Sung gulped. He felt like Young-Joon was going to ask him to give up his seat. Right now, the shareholders were absolutely on Young-Joons side. Yoon Dae-Sung had no choice but to accept it, even if Young-Joon was asking for too much, since his management abilities would be seriously questioned if he declined sloppily and the commercialization methods went to Conson & Colson. And in Young-Joons perspective, it didnt matter who made the product as he would be the one making money.
Yoon Dae-Sung had been dragged along by Young-Joon several times, but he could never stop him, even if he knew. He couldnt even imagine what it is Young-Joon wanted
Is it shares?
Young-Joon smiled as he saw Yoon Dae-Sungs tense face.
Sir, you dont have to be so tense. I have no intention of asking for too much.
Chapter 93: Cellicure 4Gu Sung-Woo, the Commissioner of the Korean Intellectual Property Office, was looking over the patent applications that came in this morning. These patents, which had been filed through the International Patent Cooperation Treaty PCT, were documents that had come for the final approval stamp.The Patent Cooperation Treaty was the standard model of international patents that pursued the protection of patents regarding inventions in more than one hundred fifty countries with an international patent treaty.The patents that Lee Hae-Won spent several nights filing was now Goo Sung-Woos problem. A large pile of documents came into his office in a small cart.What is this? he asked with wide eyes.Its CEO Ryus from A-Bio.Goo Sung-Woo covered his face with his hands after he heard the employee, who was moving the documents into his office. He figured out what this was after he heard that it was Young-Joons. This was well-known from the examination stage. They were all animal disease treatments, and there were one hundred twenty-two patents of them. The patent attorney had grouped it by disease when writing the statement instead of separating them into individual ones, but there were still thirty-two. Additionally, there were about four hundred pages for each patent statement written for every group.Is the attorney who filed these still alive? asked Goo Sung-Woo as he stacked the documents on his desk.I heard that the attorney went into Ryu Young-Joons company as the in-house patent attorney.They wrote this, and theyre still working for him?Yes.Is it like Stockholm Syndrome or something?I dont know. But the examiner used all his time off after this and disappeared....Anyways, these are all the documents about the one hundred twenty-two new drugs. They have all been approved.I didn't think they would actually all get approved. I think Ill get a cramp in my arm just from stamping it.The patent examiners from other countries probably put their blood, sweat, and tears into this.Phew. What can you do? It came in for priority review.Starting with the first drug, Goo Sung-Woo began looking over them one by one.* * *The first group of livestock infectious diseases included rinderpest, hoof-and-mouth disease, swine fever, highly pathogenic avian influenza, vesicular stomatitis, Valley fever, Bluetongue, and sheep pox. The second group of diseases included tuberculosis, Aujeszkys disease, equine infectious anemia, nausea, rabies, chronic wasting disease, anaplasma, and Duck virus hepatitis. The third group of diseases included bovine ephemeral fever, akabane disease, avian mycoplasmosis, porcine reproductive and respiratory syndrome, porcine epidemic diarrhea, avian encephalomyelitis, Mareks disease, and infectious bursal disease. It also included pet diseases for dogs and cats like the parvovirus infections and leptospirosis,Patents for one hundred twenty-two drugs for a total of thirty-two groups of diseases were approved. There were basically three drugs for one disease, and there were two reasons for this. The first was to completely prevent competitive drugs from being discovered later and patented, and the second was to use another drug as a backup in case one drug does not work due to animal specificity.These incredible drugs were examined from all over the world and approved.Ryu Young-Joon publishes patents for one hundred twenty-two types of animal diseases.A-Bio CEO Ryu Young-Joon secures one hundred twenty-two animal drug patents personally.How will all these drugs transform the livestock market and the pet industry?The news articles that were coming up one after another were more provocative than usual.Professor Shin Jung-Ju appeared on the radio for the first time in a while.CEO Ryu had commissioned these experiments to famous, mid-sized companies called Reaction Chemistry and Cell Bio. He spent over a million won on commission fees and patent publishing. And he succeeded in all of them.Is this possible? How can an individual do something like this just with experiment agencies?The interviewer asked.Usually, they cant.Some say that CEO Ryu may have registered personal patents by stealing internal data from A-Gen.Haha, conspiracy theories like that are coming out because he succeeded in publishing an unbelievable amount of patents, but they will disappear soon. It is because A-Gen has never studied animal diseases before. No matter how talented the thief is, how could they steal something that doesnt exist?Of course. But how did CEO Ryu do it?No one knows. But there is something more surprising. Its that CEO RYu requested Reaction Chemistry to design a total of one hundred twenty-two drug candidates, and the number of animal experiments commissioned to Cell Bio was one hundred twenty-two. What do you think this means?What does it mean?Mckinney read the news report to Young-Joon.It feels good to be complimented.How is the diagnostic kit going? We can do this with certainty only if we have that.We are working hard to develop it. Weve also found a way to lower the unit price as well, Young-Joon said.I see. Mr. Ryu, when will you begin production?I am on my way to meet the CEO of A-Gen to discuss that, he replied.* * *Young-Joon, who arrived at A-Gen, was alone with Yoon Dae-Sung.I knew that you were smart and you made good drugs, but I didnt know that you filed one hundred twenty-two patents without A-Gen knowing, Yoon Dae-Sung said.A-Gen had the idea, but didnt work on animal disease treatments.Those patents. Theyre not A-Bios or A-Gens, but your own, right?Yes.Yoon Dae-Sung put his hand on his head like this was trouble.Are you here to sell that to me?You also know how much money these patents will generate. They wont just be produced at A-Gen, but pharma companies all over the world that are in the livestock industry will want to pay royalties and make the drug.Of course, especially companies like Conson & Colson. They will do it since the United States is one of the countries with a powerful livestock industry.Yes. But a patent is only a patent. Its another story from commercialization. You know that, right?...Yoon Dae-Sung understood what Young-Joon was trying to say. He was trying to make a deal with commercialization while he kept the patent.I can make A-Gen the first to succeed at commercialization out of any company, Young-Joon said. The one hundred twenty-two drugs that were registered were all manufactured on the laboratory scale. They only make like five or ten milligrams. They were produced in a very rigorous process and were tested with a very pure formulation. But its not used like that in real industries. Everything changes when you manufacture a drug on a factory scale.Yes.Making a drug in a lab and manufacturing a drug in a factory was completely different. Lets say that it cost one million won to produce one dose of the drug in a lab. It couldnt be produced like that because the unit price was too expensive. The drug would be sold for over two million won including the distribution fee and profit margin in pharmacies, so who would buy something like that?As such, the process of commercialization was an essential adjustment process that reduced the cost of production for factory manufacturing. In this process, everything changed, like the reaction buffer, the boiling equipment and column. Optimizing this was also a process of research and development.As I am the developer of the one hundred twenty-two drugs, I also know how to make it into a factory scale.And you are going to hand that over to A-Gen?Yes, because I am a director of A-Gen. Its important to grow our company, right? We have to start producing before everyone else.What do you want for it? Do you want the next CTO position when Nicholas term is over and it becomes vacant?I will get that position even if you dont want me to, Young-Joon said....The shareholders will support me a lot if I reveal that I have established all the commercialization methods and are going to supply them to A-Gen for free. It will be difficult for the CTO to hand over the position to someone else after his term ends in that atmosphere.Then what do you want?Yoon Dae-Sung gulped. He felt like Young-Joon was going to ask him to give up his seat. Right now, the shareholders were absolutely on Young-Joons side. Yoon Dae-Sung had no choice but to accept it, even if Young-Joon was asking for too much, since his management abilities would be seriously questioned if he declined sloppily and the commercialization methods went to Conson & Colson. And in Young-Joons perspective, it didnt matter who made the product as he would be the one making money.Yoon Dae-Sung had been dragged along by Young-Joon several times, but he could never stop him, even if he knew. He couldnt even imagine what it is Young-Joon wantedIs it shares?Young-Joon smiled as he saw Yoon Dae-Sungs tense face.Sir, you dont have to be so tense. I have no intention of asking for too much.
